A multi-batch design to deliver robust estimates of efficacy and reduce animal use - a syngeneic tumour case study

Natasha A Karp1, Zena Wilson2, Eve Stalker2,3

  • 1Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK. Natasha.Karp@astrazeneca.com.

Scientific Reports
|April 12, 2020
PubMed

Related Concept Videos